Filter posts

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation

Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – …

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several …

Sens. Alexander and Burr Release "Innovation for Healthier Americans" Report

Today, Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) and committee member Richard Burr (R-N.C.) released …

Op-Ed in Forbes on the Threat to Philanthropy

This week, Howard Husock extols the benefits of venture philanthropy through this Forbes op-ed. In …

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey. Your investment plans and …

Chairman Upton and Rep. DeGette Op-Ed: Can We Find Cures for 7,000 Diseases?

In a CNN.com op-ed, Energy & Commerce Committee Chairman Fred Upton (R-MI) and Representative Diana …

J.P. Morgan Turns All Eyes toward Biotech

BioWorld’s Peter Winter reports that the mood is upbeat at today’s kickoff of the 33rd …

Exclusive FDA Survey Webinar

BIO is conducting an exciting new survey designed to measure FDA/Sponsor Interactions During Drug Development.  …

Don’t Go At It Alone- BIO BizLink and the Evolving R&D Marketplace

With companies in the biotechnology industry more frequently outsourcing R&D pipelines, selecting the right contract …